This study provided real-world evidence regarding the feasibility and tolerability regarding the administration of PD-1 inhibitor monotherapy for previously treated elderly patients with advanced NSCLC retrospectively. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.